ORBi: Hanssens Linda - A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder.

Reference : A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia...


	Document type :	Scientific journals : Article
	Discipline(s) :	Human health sciences : Endocrinology, metabolism & nutrition Human health sciences : Psychiatry Human health sciences : Public health, health care sciences & services
	To cite this reference:	http://hdl.handle.net/2268/6299

Title :	A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder.
Language :	English
Author, co-author :	Hanssens, Linda [> > > >]
	van Winkel, Ruud [> > > >]
	Wampers, Martien [> > > >]
	Van Eyck, Dominique [> > > >]
	Scheen, André [Université de Liège - ULg > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale >]
	Reginster, Jean-Yves [Centre Hospitalier Universitaire de Liège - CHU > > Médecine de l'appareil locomoteur >]
	Collette, Julien [Centre Hospitalier Universitaire de Liège - CHU > > Chimie médicale >]
	Peuskens, Joseph [> > > >]
	De Hert, Marc [> > > >]
Publication date :	2008
Journal title :	Schizophrenia Research
Publisher :	Elsevier
Volume :	106
Issue/season :	2-3
Pages :	308-14
Audience :	International
ISSN :	0920-9964
City :	Amsterdam
Country :	The Netherlands
Keywords :	[en] Schizophrenia ; Metabolic syndrome ; Antipsychotic ; Adiponectin ; Diabetes
Abstract :	[en] BACKGROUND: In recent years, several studies showed increased rates of hyperglycaemia, diabetes, dyslipidemia, metabolic syndrome as well as cardiovascular disease in schizophrenic patients. The underlying mechanism, however, is poorly understood. Adiponectin is a recently identified adipocyte-derived protein, with low adiponectin levels being associated with metabolic abnormalities such as obesity, insulin resistance and type 2 diabetes. METHODS: Fasting adiponectin levels were assessed in a cross-sectional sample of 386 patients with schizophrenia or schizoaffective disorder. All patients were on monotherapy of second-generation antipsychotics (SGA) and underwent an extensive metabolic screening including an oral glucose tolerance test (OGTT). RESULTS: Adiponectin plasma levels were inversely correlated with BMI, and differed significantly between patients with normal weight, overweight or obesity (p<0.05). Patients who met criteria for the metabolic syndrome, according to adapted National Cholesterol Educational Program - Adult Treatment Panel criteria (NCEP-ATP III) (29.3%), had significantly lower adiponectin levels than patients not meeting metabolic syndrome criteria (p<0.0001). Patients without glucose abnormalities (78%) had significantly higher adiponectin levels than patients with diabetes (5.7%) (p<0.05). After controlling for components of metabolic syndrome and sex, antipsychotic medication independently influenced adiponectin levels (p<0.0001), with the lowest mean levels in patients on clozapine and olanzapine. CONCLUSIONS: Adiponectin levels in schizophrenic patients mirror what is observed in the general population, with the lowest levels in the most metabolically comprised subjects. However, antipsychotic medication may also influence adiponectin regulation independently, a finding that should be confirmed in longitudinal studies.
Target :	Researchers ; Professionals
Permalink :	http://hdl.handle.net/2268/6299
	also: http://hdl.handle.net/2268/20330
DOI :	10.1016/j.schres.2008.09.008
Other URL :	http::// www.elsevier.com/locate/schres
Commentary :	All our thanks to elsevier

File(s) associated to this reference

Fulltext file(s):

	File	Commentary	Version	Size	Access
Open access	A cross-sectional evaluation of adiponectin_ocr.pdf		Author postprint	171.35 kB	View/Open

All documents in ORBi are protected by a user license.

Dspace v1.5